Contract

Exhibit 10.25

Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [     ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.

“Agreement Amendment Xx. 0”

[00 Xxxxx, 0000]

Xxxxxxx Xxxxxxxxxxxxx X.X.

Turnhoutseweg 30

B-2340 Beerse

Belgium

Elan Drug Delivery, Inc.

0000 Xxxxxxx Xxxxx

Xxxx xx Xxxxxxx, XX 00000

XXX

Dear Sirs

RE: License Agreement dated March 31, 1999 (the “Agreement”), as amended by letter amendment of July 31, 2003, between Elan Drug Delivery, Inc. (successor in interest in and to Elan Pharmaceutical Research Corp., d/b/a Nanosystems(“EDDI”) and Elan Pharma International Limited (“EPIL”)  (EDDI and EPIL collectively hereinafter referred to as “Elan”) and Xxxxxxx Pharmaceutica N.V.  (“Xxxxxxx”)

Elan and Xxxxxxx hereby agree that with effect from July 31, 2009 this Agreement Amendment No. 2 (“Agreement Amendment No. 2 Effective Date”) the Agreement shall be amended as follows:

1. All references in the Agreement to EPRC shall read EDDI.  All references to NANO shall read Elan.

2. Article 22             Elan contact details only - shall be deleted and replaced with the following:

If to Elan: Elan Pharma International Limited

EPIL Letter to Xxxxxxx and XXXX of 23 July 2009

Amendment No 2 to license dated 31 March 1999, as amended

Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [     ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.

	Monksland, Athlone, County Westmeath, Ireland
	Attention:	Vice President & Legal Counsel
	Telefax:	00 353 90 64 95402
With a copy to:	Elan Drug Delivery, Inc.
	0000 Xxxxxxx Xxxxx, Xxxx xx Xxxxxxx, XX 00000,
	XXX
	Attention:	President
	Telefax:	000 000-000-0000

3. Patent Schedules

3.1 Exhibit A: Nano Patents shall be deleted and replaced with Exhibit A:  Nano Patents — Updated January, 2011, attached hereto.

Exhibit B:  Selection Patents shall be deleted and replaced with Exhibit B Selection Patents — Updated January 2011, attached hereto.

4. Defined texts used in this Agreement Amendment No. 2 shall have the meaning assigned to them in the Agreement unless such terms are expressly defined in this Agreement Amendment No. 2.  All other provisions of the Agreement not amended herein shall remain unchanged and in full force and effect.

Yours faithfully,
Signed on behalf of:
Elan Pharma International Limited
/s/ Xxxxxxx Xxxxxx
Name:	Xxxxxxx Xxxxxx
Title:	Director
Date:	1 April 2011

Agreed and accepted for and on behalf of

Elan Drug Delivery, Inc. successor in interest in and to Elan Pharmaceutical Research Corp., d/b/a Nanosystems

2

Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [     ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.

/s/ Xxxxx Xxxxxx

Name: Xxxxx Xxxxxx

Title: VP and GM

Date: 18 Apr 2011

Accepted for and on behalf of:

Xxxxxxx Pharamceutica N.V.

/s/ Ludo Lauwers

Name: Ludo Lauwers

Title: Senior Vice President, Site Management

Date: 17 March 2011

/s/ Xxxx Xxxxxxx

Member of the Board

3

Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [     ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.

Exhibit A: Nano Patents—Updated January, 2011

[*****]

4

Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [     ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.

[Exhibit B: Selection Patents—Updated July 31, 2009]

[*****]

5